{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:01:27Z","timestamp":1790766087851,"version":"4.1.0"},"reference-count":25,"publisher":"XMLink","issue":"3","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["tcpharm.org"],"crossmark-restriction":false},"short-container-title":["Transl Clin Pharmacol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.12793\/tcp.2026.34.e13","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:04:36Z","timestamp":1790733876000},"page":"129","update-policy":"https:\/\/doi.org\/10.12793\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Motility-mediated drug interactions with GLP-1 receptor agonists: labeled evidence and a framework for quantitative assessment"],"prefix":"10.12793","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-2786","authenticated-orcid":false,"given":"Jae Yong","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18617","reference":[{"key":"10.12793\/tcp.2026.34.e13_ref1","doi-asserted-by":"crossref","DOI":"10.15620\/cdc\/174616","volume-title":"GLP-1 injectable use among adults with diagnosed diabetes: United States, 2024. NCHS Data Brief No. 537","author":"Vahratian","year":"2025"},{"key":"10.12793\/tcp.2026.34.e13_ref2","volume-title":"Byetta (exenatide): US prescribing information. NDA 021773","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref3","volume-title":"Bydureon BCise (exenatide extended-release): US prescribing information. NDA 209210","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref4","volume-title":"Adlyxin (lixisenatide): US prescribing information. NDA 208471","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref5","volume-title":"Mounjaro (tirzepatide): US prescribing information. NDA 215866","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref6","volume-title":"Rybelsus (semaglutide): US prescribing information. NDA 213051","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref7","volume-title":"Foundayo (orforglipron): US prescribing information. NDA 220934","author":"US Food and Drug Administration","year":"Revised July 2026"},{"key":"10.12793\/tcp.2026.34.e13_ref8","volume-title":"Trulicity (dulaglutide): US prescribing information. BLA 125469","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref9","volume-title":"Victoza (liraglutide): US prescribing information. NDA 022341","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref10","volume-title":"Ozempic (semaglutide): US prescribing information. NDA 209637","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref11","volume-title":"Soliqua 100\/33 (insulin glargine and lixisenatide): US prescribing information. NDA 208673","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref12","volume-title":"Xultophy 100\/3.6 (insulin degludec and liraglutide): US prescribing information. NDA 208583","author":"US Food and Drug Administration","year":"2026"},{"key":"10.12793\/tcp.2026.34.e13_ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.12793\/tcp.2026.34.e13_ref14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.14309\/ajg.0000000000002820","volume":"119","author":"Hiramoto","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.12793\/tcp.2026.34.e13_ref15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"key":"10.12793\/tcp.2026.34.e13_ref16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrendo.2014.202","volume":"11","author":"Phillips","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.12793\/tcp.2026.34.e13_ref17","volume-title":"Drug interaction studies M12","author":"International Council for Harmonisation","year":"2024"},{"key":"10.12793\/tcp.2026.34.e13_ref18","unstructured":"US Food and Drug Administration. Clinical drug interaction studies with combined oral contraceptives: guidance for industry [Internet]. Accessed August 30, 2026.  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-combined-oral-contraceptives-guidance-industry"},{"key":"10.12793\/tcp.2026.34.e13_ref19","unstructured":"US Food and Drug Administration. Evaluation of gastric pH-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications: guidance for industry [Internet]. Accessed August 30, 2026.  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis"},{"key":"10.12793\/tcp.2026.34.e13_ref20","volume-title":"Concept paper on a guideline on investigation of drug interactions in the gastrointestinal tract. EMA\/124631\/2025","author":"European Medicines Agency","year":"2025"},{"key":"10.12793\/tcp.2026.34.e13_ref21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s11239-026-03310-7","volume":"59","author":"Gilbert","year":"2026","journal-title":"J Thromb Thrombolysis"},{"key":"10.12793\/tcp.2026.34.e13_ref22","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.japh.2024.102185","volume":"64","author":"Wilcox","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.12793\/tcp.2026.34.e13_ref23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/phar.70007","volume":"45","author":"Hooper","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.12793\/tcp.2026.34.e13_ref24","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/psp4.70101","volume":"14","author":"Posada","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.12793\/tcp.2026.34.e13_ref25","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cpt.3561","volume":"117","author":"Hopefl","year":"2025","journal-title":"Clin Pharmacol Ther"}],"container-title":["Translational and Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tcpharm.org\/pdf\/10.12793\/tcp.2026.34.e13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2026.34.e13","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2026.34.e13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:17:26Z","timestamp":1790763446000},"score":1,"resource":{"primary":{"URL":"https:\/\/tcpharm.org\/DOIx.php?id=10.12793\/tcp.2026.34.e13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.12793\/tcp.2026.34.e13","relation":{},"ISSN":["2289-0882","2383-5427"],"issn-type":[{"value":"2289-0882","type":"print"},{"value":"2383-5427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"2026-08-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"Copyright \u00a9 2026 Translational and Clinical Pharmacology","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"It is identical to the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/).","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}